NCT01386970View on ClinicalTrials.gov

Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics

PHASE4CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2010

Conditions
HIV
Interventions
DRUG

zidovudine 300mg and lamivudine 150mg as Combivir

twice daily for 12 days in the HIV-negative group and indefinitely for their care in the HIV-positive group

Trial Locations (1)

80045

University of Colorado Denver and Health Sciences Center, Aurora

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

University of Hawaii

OTHER

lead

University of Colorado, Denver

OTHER

NCT01386970 - Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics | Biotech Hunter | Biotech Hunter